Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

More Women Than Men Develop HF or Die After STEMI

News Daily News

More Women Than Men Develop HF or Die After STEMI

December 01, 2020

TCTMD’s Top 10 Most Popular Stories for November 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2020

November 30, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

News Conference News AHA 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

September 22, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

News Daily News

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

Yael L. Maxwell

August 19, 2020

Both CV Risk Factors, Complications Herald Higher COVID-19 Mortality

News Daily News

Both CV Risk Factors, Complications Herald Higher COVID-19 Mortality

August 19, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

Higher Risk of HF After ACS for Women Previously on Beta-blockers

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

Too Many HF Trial Results Underreported or Never Published

News Daily News

Too Many HF Trial Results Underreported or Never Published

June 23, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

TCTMD’s Top 10 Most Popular Stories for February 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2020

March 02, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.